恩度联合含铂类化疗方案治疗晚期非小细胞肺癌的临床观察

目的：观察恩度联合含铂类化疗方案治疗晚期非小细胞肺癌患者的近期疗效、不良反应及与患者预后的关系。方法：27例晚期非小细胞肺癌患者中，鳞癌15例，腺癌12例，给予NP（14例）、DP（7例）、TP（6例）方案化疗同时联合恩度7．5mg／m2，连用14d，休息1周。21d为1周期，均至少完成2周期，观察近期疗效、1年生存率、疾病进展时间及不良反应。结果：27例患者中部分缓解11例（40．7％），稳定10例（37．0％），进展6例（22．2％），有效率为40．7％，临床受益率为77．8％。中位疾病进展时间为4．4个月，中位生存期为11．0个月，1年生存率为37．0％。不良反应主要为骨髓抑制和消化道毒性，发生Ⅲ～Ⅳ度贫血2例（7．4％），III～IV度呕吐2例（7．4％），发生I度ST—T改变3例（11．1％）。结论：恩度联合含铂类化疗方案一线治疗晚期非小细胞肺癌是一种合理、安全、有效的方案，且可以改善患者预后。

Clinical study on endostar combined platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer

Objective： To observe the efficacy and safety of endostatin injection （endostar） combined with platinum-based regimen in patients with advanced non-small cell lung cancer （NSCLC）. Methods： Twenty-seven histologically confirmed stage II B and IV NSCLC patients were enrolled in the group, including 15 cases with squamons cell carcinoma, 12 cases with adenocarcinoma. There were 14 patients administrated with endostar plus NP regimen, 7 patients administrated with endostar plus DP regimen and 6 patients administrated with endostar plus TP regimen （ endostar 7.5mg/m2 day 1 to 14, repeated 21 days）. All patients should completed 2 cycles at least.The goals were the therapeutic effects, one year survival rate, the median time to progress and adverse reactions. Results： Among 27 cases, there were 11 cases PR（ 40.7% ）, 10 cases SD （37.0%） and 6 cases PD （22.2%）. Overall response rate was 40.7%, the clinical benefit rate was 77.8% ,TTP was 4.4 months, median survival time was 11.0 months,and one-year survival rate was 37.0%. The main toxicities were leucopenia and nausea/vomiting.The G3-G4 toxicities including anemia 2 caces （7.4%） , vomiting 2 cases （7.4%）. Three cases occurred G1 ST-T change （11.1%）. Conclusion： Endostar combined with platinum-based regimen were efficient and safe in the treatment of advanced NSCLC. It may be worthy of further clinical investigation.